Summary of Cardiol Therapeutics FY Conference Call Company Overview - **Company**: Cardiol Therapeutics (NasdaqCM:CRDL) - **Focus**: Targeting inflammation in heart disease, particularly recurrent pericarditis and myocarditis, with a pipeline that includes late-stage and early-stage drug developments [2][3] Key Points Industry and Market Opportunity - **Heart Disease Landscape**: Heart failure is a significant health challenge, with a 50% five-year mortality rate, driven by obesity, diabetes, and hypertension [6] - **Market Potential**: Immunosuppressants for recurrent pericarditis are generating approximately $700 million annually, with forecasts suggesting they could reach $1 billion by 2028. Cardiol Therapeutics anticipates capturing a significant share of this market with its oral, non-immunosuppressive drug [19][20] Product Development - **Lead Program**: MAVERIC study focuses on recurrent pericarditis, with enrollment accelerating and significant near-term catalysts expected [4][5] - **Clinical Trials**: The Phase 2 program showed a 70% reduction in recurrence rates, and the ongoing Phase 3 trial is conservatively powered to achieve a 35%-40% reduction, which is considered a positive outcome by experts [32] - **ARCHER Trial**: Recent data from the ARCHER trial indicates a biological impact on myocarditis, which could open doors for new cardiovascular indications [20][21] Clinical Efficacy - **Pain Management**: In the Phase 2 trial, patients experienced a significant reduction in pericarditis pain, with 71% remaining recurrence-free during the study [13][14] - **C-Reactive Protein (CRP)**: Notable reduction in CRP levels, indicating a decrease in inflammation, was observed, with levels approaching normal by 8 weeks [12][14] - **Left Ventricular Mass**: The ARCHER trial demonstrated a significant reduction in left ventricular mass, correlating with improved cardiovascular outcomes [25][26] Regulatory and Commercialization Strategy - **FDA Alignment**: The company has received positive feedback from the FDA regarding the design of the MAVERIC trial, which could support a New Drug Application (NDA) upon successful outcomes [15][33] - **Market Positioning**: CardiolRx is positioned as a second-line treatment option, preferred by physicians due to its non-immunosuppressive nature and ease of access compared to existing therapies [34] Future Directions - **Next Generation Products**: CRD-38, a once-monthly subcutaneous formulation, is in development to address heart failure, targeting inflammation and fibrosis [28][30] - **Strategic Alliances**: The company is actively seeking partnerships to enhance its market presence and accelerate the development of its drug assets [4][30] Additional Insights - **Patient-Centric Approach**: The focus on oral medication and reducing dependency on immunosuppressants aligns with patient preferences for convenience and safety [10][34] - **Expert Collaboration**: The involvement of leading cardiovascular researchers and institutions enhances the credibility and potential success of Cardiol Therapeutics' clinical programs [18][23] This summary encapsulates the critical aspects of Cardiol Therapeutics' conference call, highlighting the company's strategic focus, product development, clinical efficacy, and market positioning within the heart disease landscape.

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's prese ...

Core Insights - Cardiol Therapeutics Inc. has published results from its Phase II ARCHER study, demonstrating the efficacy of its lead drug candidate, CardiolRx™, in treating acute myocarditis, which is a significant cause of heart failure in young adults [1][2][3] Company Overview - Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [6][9] - The company is also developing CRD-38, a novel subcutaneously administered drug formulation aimed at treating inflammatory heart disease, including heart failure, which incurs healthcare costs exceeding US$30 billion annually in the U.S. [9] Study Findings - The Phase II ARCHER study involved 109 patients and showed that treatment with CardiolRx™ resulted in a significant reduction in left ventricular mass by 9.2 grams compared to placebo (p=0.0117), alongside decreased left atrial remodeling and favorable trends in myocardial inflammation markers [3][4] - The safety and tolerability of CardiolRx™ were confirmed in the study, indicating its potential to improve clinical outcomes in myocarditis patients [3] Ongoing Trials - The biological signals observed in the ARCHER study are relevant to Cardiol's ongoing pivotal Phase III MAVERIC trial, which focuses on recurrent pericarditis, an inflammatory disease of the pericardium [4][7] - The MAVERIC program includes the completed Phase II MAvERIC-Pilot study and the ongoing Phase III MAVERIC trial, with the U.S. FDA granting Orphan Drug Designation to CardiolRx™ for recurrent pericarditis [7] Management Commentary - The CEO of Cardiol Therapeutics emphasized that the publication of the ARCHER study results enhances confidence in the MAVERIC trial and highlights CardiolRx's impact on inflammatory heart disease [5]

Core Viewpoint - Cardiol Therapeutics Inc. has successfully completed a private placement of units, raising a total of $14.85 million to support its research and clinical development programs for heart disease therapies [1][3]. Financing Details - The company issued 11,423,078 units at a price of $1.30 per unit, which includes the full exercise of the over-allotment option by the underwriter [1]. - Each unit consists of one Class A common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The underwriter received a cash commission of 6% of the aggregate gross proceeds from the offering [2]. Use of Proceeds - The net proceeds from the financing will be utilized to advance research and clinical development programs, as well as for general administrative expenses and working capital [3]. Regulatory Compliance - The offering was conducted as a private placement under National Instrument 45-106, allowing sales to qualified investors in Canada, excluding Quebec [4]. - The units issued are not subject to resale restrictions in Canada under applicable securities laws [4]. Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis associated with heart conditions [6]. - The company is conducting the MAVERIC Program to evaluate CardiolRx™ for recurrent pericarditis and has received Orphan Drug Designation from the U.S. FDA for this treatment [7]. - Additionally, the ARCHER Program is studying CardiolRx™ for acute myocarditis, a significant cause of heart failure in young adults [8]. - Cardiol is also developing CRD-38, a novel subcutaneous drug formulation for inflammatory heart disease, addressing a major healthcare cost issue in the U.S. [9].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4]. Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including TSX approval, and the negotiation of an underwriting agreement [4]. - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the company's research and clinical development programs, as well as for general and administrative expenses and working capital [3]. Group 3: Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10]. - The company is also developing CRD-38, a novel drug formulation for treating inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4] Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2] - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including from the TSX [4] - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing [4] Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance research and clinical development programs, as well as for general administrative expenses and working capital [3] Group 3: Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10] - The company is also developing CRD-38, a novel drug formulation for inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12]

Core Insights - Cardiol Therapeutics Inc. has surpassed 50% patient enrollment in its Phase III MAVERIC trial, which evaluates CardiolRx™ for preventing disease recurrence in patients with recurrent pericarditis [1][2][3] Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [5][9] - The company aims to address the high unmet medical need in recurrent pericarditis, a condition that significantly impacts patients' quality of life [7] Clinical Trial Progress - The MAVERIC trial is designed to enroll approximately 110 patients across 25 leading cardiovascular research centers in the U.S., Canada, and Europe, with full enrollment expected by Q2 2026 [4][6] - The primary endpoint of the trial is freedom from new episodes of recurrent pericarditis after six months of treatment, with secondary endpoints including pain scores and inflammatory biomarker changes [4] Scientific Rationale and Market Potential - Data from the Phase II MAvERIC-Pilot study showed that CardiolRx™ led to rapid and sustained reductions in pericarditis pain and inflammation, supporting its advancement to Phase III [3][4] - The company believes that CardiolRx™'s oral, non-immunosuppressive profile positions it as a more accessible treatment option compared to biologic therapies, which are projected to generate over $800 million in U.S. revenues in 2026 [3][4]

Summary of Cardiol Therapeutics Archer Phase 2 Webcast Conference Call Company Overview - **Company**: Cardiol Therapeutics (NasdaqCM:CRDL) - **Focus**: Late-stage clinical development of novel therapies for inflammatory heart disease, particularly acute myocarditis, recurrent pericarditis, and heart failure [4][5][24] Key Industry Insights - **Industry Context**: The call discussed the ARCHER trial, a significant clinical study in the field of myocarditis, which is a serious inflammatory heart condition that can lead to heart failure [2][4][8] - **Market Potential**: The market for treatments related to inflammatory heart diseases is substantial, with estimates for IL-1 blockers exceeding $600 million in annual sales in the US, potentially reaching $1 billion by 2027-2028 [36] Core Findings from the ARCHER Trial - **Trial Design**: The ARCHER trial was a phase 2, multi-center, randomized, double-blind, placebo-controlled study involving 109 patients across 34 centers [14][8] - **Primary Endpoints**: The trial aimed to evaluate the safety, tolerability, and efficacy of Cardiol Rx, focusing on cardiac magnetic resonance imaging (CMR) endpoints [13][14] - **Key Results**: - **Extracellular Volume (ECV)**: A reduction of 3.7 mL was observed, indicating decreased inflammation and fibrosis [16][17] - **Intracellular Volume (ICV)**: A reduction of 5.6 mL was noted, suggesting reduced cellular swelling and edema [17] - **Left Ventricular Mass (LVM)**: A significant reduction of over 9 grams in LVM was achieved, which is comparable to reductions seen with established therapies for heart conditions [19][20] - **Safety Profile**: Cardiol Rx demonstrated a strong safety profile, with adverse event rates comparable to placebo [21][22] Implications of Findings - **Clinical Relevance**: The reductions in ECV, ICV, and LVM suggest meaningful structural recovery in patients with acute myocarditis, potentially improving clinical outcomes [20][21][23] - **Translational Insights**: The findings support the hypothesis that Cardiol Rx can remodel the heart by targeting myocardial inflammation, which is crucial for the progression of heart disease [23][28] - **Future Directions**: The results bolster confidence in ongoing trials, particularly the pivotal phase 3 MAVERICK trial for recurrent pericarditis, and highlight the potential for the next-generation drug candidate CRD38 [24][31] Expert Commentary - **Dr. Dennis McNamara**: Emphasized the significance of the ARCHER trial in demonstrating structural changes with therapeutic intervention in myocarditis [26][27] - **Dr. Leslie Cooper**: Highlighted the study's robust design and the importance of the findings in supporting further development for inflammatory heart conditions [28] Next Steps for Cardiol Therapeutics - **Ongoing Trials**: Focus on executing the MAVERICK trial and accelerating the development of CRD38 for heart failure [36][38] - **Market Strategy**: Engage with pharmaceutical companies interested in heart failure medicine to explore partnerships for the next-generation drug candidate [31][38] Conclusion - The ARCHER trial results represent a significant advancement in the treatment of inflammatory heart diseases, with promising implications for future clinical applications and market opportunities [22][24][39]

Core Insights - Cardiol Therapeutics Inc. announced significant findings from the Phase II ARCHER trial, demonstrating that CardiolRx™ improves heart structure in patients with acute myocarditis, supporting its potential for broader applications in inflammatory cardiac conditions [2][4][5] Group 1: Trial Results - The ARCHER trial showed a significant reduction in left ventricular (LV) mass by 9.2 grams (from 130.3g in placebo to 121.1g in the active group, p=0.0117), indicating meaningful structural recovery [3][8] - Extracellular volume (ECV) decreased by 3.7 mL (from 37.3mL in placebo to 33.6mL in the active group, p=0.0538), and intracellular volume (ICV) reduced by 5.6 mL (from 91.2mL in placebo to 85.6mL in the active group, p=0.0928) [8][9] - Left atrial end systolic volume (LAESV) was reduced by 8.1 mL (p=0.0376) and left ventricular end diastolic volume (LVEDV) decreased by 7.4 mL (p=0.0981), reflecting improved heart function [8][9] Group 2: Clinical Implications - The results provide clinical evidence that CardiolRx™ can reduce inflammation-driven structural damage in the heart, a key factor in heart failure progression [4][5] - The findings support the scientific rationale for Cardiol's lead Phase III program in recurrent pericarditis and indicate potential for development across various inflammatory cardiac conditions [4][5][17] Group 3: Company Overview - Cardiol Therapeutics is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with CardiolRx™ as its lead candidate [15][18] - The company is also advancing CRD-38, a next-generation small molecule targeting chronic inflammatory heart conditions [18]